<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>St. Louis encephalitis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">St. Louis encephalitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">St. Louis encephalitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas P Monath, MD, FACP, FASTMH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 30, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>St. Louis encephalitis (SLE) is an acute, mosquito-borne viral illness characterized by meningeal and brain parenchymal inflammation and injury. The disease occurs in endemic and epidemic form in North and South America. Epidemics of SLE in the United States have been responsible for at least 1,000,000 mild or subclinical infections, 10,000 clinical cases, and 1000 deaths since SLE virus was first isolated in 1933 during an outbreak in St. Louis, Missouri [<a href="#rid1">1</a>].</p><p>Studies of SLE virus evolution indicate that the virus was introduced into North America from tropical America in the late 19th Century [<a href="#rid2">2</a>]. There is evidence that West Nile (WN) virus, which was introduced into the United States in 1999, has displaced SLE by more efficient transmission and cross-protective immunity in wild birds [<a href="#rid3">3,4</a>]. The annual incidence of SLE and the occurrence of epidemics have substantially declined as WN virus has spread throughout North America, although small outbreaks occurred in Southern California and Arizona between 2015 and 2017 [<a href="#rid5">5</a>]. In contrast, there are increasing reports of SLE infections in tropical America.</p><p class="headingAnchor" id="H2"><span class="h1">VIROLOGY</span><span class="headingEndMark"> — </span>SLE virus is a member of the family <em>Flaviviridae</em>, a group of small (40 to 60 nm), enveloped, positive-sense, single-stranded RNA viruses that replicate in the cytoplasm of infected cells. Other members of this virus family include West Nile (WN) virus, Japanese encephalitis (JE) virus, Murray Valley encephalitis virus, yellow fever virus, and dengue virus. SLE virus grows in a wide variety of avian and mammalian cell cultures and causes lethal encephalitis in infant mice or hamsters after intracerebral inoculation. SLE virus is antigenically closely related to JE and WN virus, which cause a similar disease (see  <a class="medical medical_review" href="/z/d/html/1293.html" rel="external">"Arthropod-borne encephalitides"</a>). This may result in diagnostic confusion, particularly if nonspecific serological tests are used. (See <a class="local">'Diagnosis'</a> below.)</p><p>SLE virus strains from the eastern and western United States and from tropical America are distinguishable at the nucleotide sequence level into at least eight genotypes and multiple clades [<a href="#rid6">6-8</a>]. Strains of SLE virus also differ with respect to the mosquito vectors responsible for transmission and the virulence for animal models [<a href="#rid9">9</a>] and wild avian hosts. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Genotypes I and II are prevalent in the United States and are associated with epidemic disease. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genotype III is found in southern South America and has been associated with human disease outbreaks in California and Arizona [<a href="#rid5">5</a>]. Strains of this genotype have shown high virulence markers in animal experiments [<a href="#rid10">10</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genotypes IV, VI, VII, and VIII have limited distributions in South America, while genotype V is widely distributed in the continent [<a href="#rid8">8</a>].</p><p></p><p>Although there is evidence for geographic separation and local persistence of strains (eg, Lineage I in California), analyses of SLE virus evolution suggest flow of neotropical strains, particularly from northern Central America, Mexico, and the Caribbean, into the United States by the agency of migratory birds [<a href="#rid7">7,11</a>]. One analysis identified circulation of an ancestral genotype of SLE circulating in <em>Culex nigripalpus</em> in southern Mexico, which may have given rise to cosmopolitan virus genotypes [<a href="#rid11">11</a>]. In California, where circulation of SLE was apparently absent from 2003 to 2014, the virus reappeared in 2015, along with an outbreak in neighboring Arizona [<a href="#rid12">12</a>]. The virus was genetically most closely related to a strain isolated during an outbreak in Argentina in 2005, suggesting it had been introduced by migratory birds [<a href="#rid5">5,13</a>]. Subsequent studies have confirmed the origin of the 2015 outbreak and have shown that Lineage III viruses have persisted in the Southwestern United States and have been responsible for interstate spread [<a href="#rid14">14,15</a>]. </p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>After inoculation of SLE virus into the human host via mosquito saliva, viral replication is initiated in local tissues and regional lymph nodes. The early steps in pathogenesis after inoculation in mosquito saliva have been partially elucidated for West Nile (WN) virus, and it is likely that the same mechanisms apply in the case of SLE. Mosquito saliva contains factors that enhance virus replication by diminishing innate immune responses and by recruiting susceptible target cells [<a href="#rid16">16</a>]. Subsequent spread of the virus occurs initially to extraneural tissues via the lymphatics and blood. SLE virus replicates in a wide array of cell types, including connective tissue, skeletal muscle, exo- and endocrine glands, and reticuloendothelial tissues. Viremia is terminated approximately one week after infection by neutralizing antibodies and cytotoxic T cells.</p><p>The mechanism by which SLE virus reaches the brain remains uncertain, but may include direct invasion at sites of compromised microvasculature or at the choroid plexus, where the endothelium is "fenestrated." In animal models, neuroinvasion appears to precede disruption of the blood-brain barrier; the olfactory neurons became infected early during the course of viremic infection, with subsequent axonal transport of virions to the olfactory lobe of the brain [<a href="#rid17">17</a>]. After the virus reaches the brain, infection spreads rapidly. Retrograde axonal transport from peripheral nerves to the spinal cord [<a href="#rid18">18</a>] may explain the occurrence of myelitis in cases of SLE [<a href="#rid19">19</a>]. As shown for WN virus in the mouse model, immune activation (through toll-like receptor 3) may play a critical role in neuroinvasion [<a href="#rid20">20</a>].</p><p>Neuronal damage is probably mediated in part by caspase-3-dependent apoptosis, as shown for WN, Japanese encephalitis (JE), and other flaviviruses [<a href="#rid21">21</a>]. The increased susceptibility of elderly persons to SLE virus (see <a class="local">'Epidemiology'</a> below) may be due to mechanical factors (eg, hypertension, atherosclerosis) that compromise the integrity of the blood-brain barrier or to reduced immune responsiveness. Overactivity of angiotensin I-converting enzyme (ACE-1) in advanced age may exacerbate a pathological host response to infection, as suggested for WN [<a href="#rid22">22</a>]. Increased production of ACE-1 results in increased angiotensin II, a powerful pro-inflammatory cytokine.</p><p>Most infections with SLE are subclinical. The hereditary and acquired factors responsible for overt and severe infection in a small subset of patients remain unknown. However, there is a substantial body of knowledge indicating that the type I interferon (IFN-I) system is critical to limiting the severity of infection, and it is likely that genetic factors influencing expression of receptors and transcription factors involved in the induction of interferons and inflammatory cytokines could be responsible for the outcome of infection. </p><p>Mice deficient in IFN-I receptors, interferon transcription factors, and RIG-I receptor family genes are also highly susceptible to flavivirus infection [<a href="#rid23">23,24</a>]. Susceptibility of mice to flavivirus infection has been linked to genes controlling 2', 5' oligoA synthetase, the antiviral factor induced by interferon, but the role of this gene in humans is uncertain. </p><p>Genetic susceptibility to fatal infection with WN virus in humans was linked to homozygosity for CCR5Delta32, a nonfunctional variant of chemokine receptor CCR5 [<a href="#rid25">25</a>]. A fatal case of another flavivirus infection (yellow fever vaccine-associated viscerotropic disease) was also associated with a possible defect in CCR5 and its ligand RANTES, which might have altered trafficking of CD8+ cells important to the antiviral immune response [<a href="#rid26">26</a>]. Experimental studies of WN infection indicate that trafficking of specific CD8+ T cells to the brain is critical to recovery and survival [<a href="#rid27">27,28</a>]. Cases of SLE have been reported in patients with HIV-1 infection, suggesting that impairment of T cell responses may have contributed to neuroinvasion or diminished viral clearance [<a href="#rid29">29</a>]. In the 2015 outbreak of SLE in Maricopa County, Arizona, 3 of 23 confirmed SLE cases occurred in organ transplant recipients, and one patient died [<a href="#rid13">13</a>].</p><p>Recovery from infection is mediated by neutralizing antibodies and CD8+ T cells [<a href="#rid30">30</a>]. In cases with central nervous system (CNS) infections, CD8+ T cells are recruited across the blood-brain barrier to clear virus from brain tissue. This appears to be under the control of the cytokine CXCR4 on endothelial cells and its receptor CXCR4 on lymphocytes [<a href="#rid27">27</a>]. Infection with SLE virus results in a long-lasting neutralizing antibody response that is responsible for protection against reinfection. Persistent infection with SLE, with prolonged viruria and kidney infection, has been demonstrated in hamsters [<a href="#rid31">31</a>]. Although there are no data indicating that this occurs in humans, this may simply reflect a lack of attempts to investigate the phenomenon. SLE antigen and virus particles were found in urinary sediment from SLE patients during the acute phase of the disease [<a href="#rid32">32</a>]. Persistent shedding of WN RNA in urine for up to nine years has been described and is associated with a higher risk of chronic kidney disease [<a href="#rid33">33</a>]; similar studies with SLE have not been conducted. Chronic infections of humans, sometimes with neurologic consequences, have been reported for related flaviviruses (Zika, JE, and tick-borne encephalitis).</p><p class="headingAnchor" id="H4"><span class="h2">Pathology</span><span class="headingEndMark"> — </span>SLE virus produces a lymphocytic meningitis; pathologic changes in the brain, particularly the gray matter, include perivascular lymphocytic infiltrates, cellular nodules, and neuronal degeneration. While lesions are distributed throughout the brain, the most severely affected regions are the hypothalamus, cerebellar and cerebral cortex, basal ganglia, brainstem, and cervical spinal cord [<a href="#rid19">19,34</a>]. Rarely, SLE may present as acute demyelinating encephalomyelitis (ADEM) with prominent lesions in white matter [<a href="#rid35">35</a>]. Pathologic changes in extraneural tissues have not been described.</p><p class="headingAnchor" id="H5"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>SLE virus is widely distributed in the Americas. In temperate areas, SLE occurs during the summer months when mosquito vectors are active and peaks during August and September. Transmission may occur as late as December in warmer climates, such as Florida and southern California. Prior infection with dengue virus does not cross-protect against SLE.</p><p>SLE was a leading cause of epidemic viral encephalitis in the United States prior to the spread of West Nile (WN) virus, with more than 10,000 SLE cases reported over the last five decades. Epidemics occurred principally in the Ohio-Mississippi valley, eastern Texas, and Florida. A large outbreak occurred in 1933 in St. Louis, Missouri with over 1000 cases. A widespread SLE outbreak occurred in 1975 involving 2800 cases in 31 states. Attack rates during epidemics in the eastern United States ranged widely from 5 to 200 per 100,000 people. The highest attack rates have been reported in outbreaks affecting small towns. Occasional epidemics have also been reported in southeastern Canada and northern Mexico.</p><p>The incidence of SLE appears to have significantly diminished over the last decade, apparently due to interference by WN virus [<a href="#rid36">36</a>]. WN virus, which was introduced into the United States in 1999, is strongly cross-protective against SLE in shared avian host species and is transmitted more efficiently by vectors [<a href="#rid3">3,37</a>]. As an example, the annual incidence of SLE prior to the introduction and spread of WN virus varied from 0.003 to 0.752 per 100,000 population with a median number of approximately 35 reported cases per year [<a href="#rid38">38,39</a>]. However, from 2010 to 2014, the reported incidence of SLE in the United States has been 10, 6, 3, and 10 cases, respectively [<a href="#rid40">40-43</a>]. However, in 2015, an outbreak occurred in the Phoenix, Arizona area, with 23 confirmed cases (<a class="graphic graphic_figure graphicRef122372" href="/z/d/graphic/122372.html" rel="external">figure 1</a>) [<a href="#rid12">12</a>].</p><p>There are increasing reports of SLE infections in tropical America. Prior to 2005, only sporadic cases were reported from tropical America. However, there have subsequently been several outbreaks of human disease caused by genotype III in Brazil and Argentina [<a href="#rid44">44-46</a>]. Sporadic human cases have also been reported from Central America and Peru.</p><p class="headingAnchor" id="H6"><span class="h1">TRANSMISSION CYCLE</span><span class="headingEndMark"> — </span>In the United States and contiguous areas, SLE virus is transmitted by several species of <em>Culex</em> vector mosquitoes. The intermediate hosts are wild birds, principally small passerine species. Despite the reduced incidence of SLE in North America in the past 15 years, there is evidence for continued circulation of the virus in wild bird populations [<a href="#rid13">13,47</a>]. Thus, re-emergence of SLE remains a threat where conditions are favorable, such as the introduction of a virulent virus strain (as apparently happened in California and Arizona from 2015 to 2017 [<a href="#rid13">13</a>]) and/or a decrease in West Nile (WN) virus activity. Horses do not contribute to transmission of SLE virus, although these animals can have a high prevalence of antibodies indicating widespread subclinical infections. There is a single report of a horse in Brazil with neurological infection cause by SLE [<a href="#rid48">48</a>].</p><p>Humans are tangentially infected by mosquitoes that have fed on viremic birds and are dead-end hosts with respect to the transmission cycle. An extrinsic incubation period of 7 to 10 days is required in the mosquito vector between feeding on a viremic bird and infectivity for a second host. This interval is shortened by high environmental temperature. Compared to WN virus, SLE infection of wild birds results in a lower viremia; this fact and a narrower avian host range for the virus explain the lower transmission rates and incidence of human infection.</p><p>The biting habits and distribution of mosquito vector species, as well as virulence properties of the virus, are responsible for epidemiologic differences of the disease in different geographic regions.</p><p class="bulletIndent1"><span class="glyph">●</span>In the eastern United States (except Florida), the principal epidemic vectors are two closely related mosquito species (<em>Culex pipiens</em> and <em>Culex quinquefasciatus</em>) that breed ubiquitously in drainage ditches and other collections of polluted water in urban-suburban habitats. Vector densities may be high, and the mosquito bites in and around houses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In Florida, <em>Culex nigripalpus</em> is the principal vector which breeds in a wide variety of habitats, including swamps and drainage ditches. This mosquito bites mainly outdoors and may attain relatively high densities in wooded suburban habitats and parks in cities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the western United States, SLE virus is transmitted by <em>Culex tarsalis</em>, which breeds in irrigated farmland. Human infections tend to occur in a sporadic or endemic pattern linked to outdoor exposure in rural areas where the enzootic cycle is maintained. In suburban and urban environments, <em>Culex pipiens</em> and <em>Culex quinquefasciatus</em> may be responsible for transmission.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In Argentina and Brazil, outbreaks appear to be transmitted in a similar cycle involving birds and <em>Culex quinquefasciatus </em>and<em> Culex interfor</em>. However, it is likely that more complex cycles of transmission involve mammals, and as yet, poorly defined mosquito species.</p><p></p><p>SLE virus can be found every summer in mosquitoes and birds in the United States, but outbreaks have often occurred at intervals of 3 to 10 years, often affecting different localities [<a href="#rid38">38</a>]. The ecologic reasons for the increased virus amplification in epidemic years remain obscure, but probably involve a confluence of factors including rainfall and environmental temperature patterns that affect mosquito and avian host density and virus transmission rate. </p><p>In the eastern United States, spring to early summer drought conditions favor breeding of <em>Culex</em> vectors in concentrated sites. This also attracts congregation of avian hosts; summer rains expand vector populations and have been associated with SLE outbreaks [<a href="#rid38">38,49</a>]. As described above, interference by WN virus immunity in avian populations may play a more important role in determining the force of infection of SLE virus than environmental factors. (See <a class="local">'Epidemiology'</a> above.)</p><p>The bird species involved in SLE amplification appear to differ in North America and in Argentina, with <em>Passeriformes</em> (eg, the domestic sparrow <em>Passer domesticus</em>) playing a central role in the former and <em>Columbiformes</em> (dove) species in the latter [<a href="#rid50">50</a>].</p><p>Laboratory-acquired infection by aerosol exposure has been extremely rare. The virus is not shed in human secretions, and there are no recorded instances of person-to-person spread. SLE antigen is found in the urine of patients [<a href="#rid32">32</a>], but this is unlikely to be associated with transmission. The virus is not found in blood after the appearance of neurologic signs, and blood does not pose a significant infectious hazard in hospitals. SLE acquired by blood transfusion has rarely been described [<a href="#rid17">17</a>]. </p><p>However, neuroinvasive SLE was reported in three unrelated solid organ transplant recipients during the SLE outbreak in Arizona, emphasizing the potential for transmission from donors with unrecognized infection to immunocompromised individuals [<a href="#rid51">51</a>]. In addition, prolonged shedding of Zika virus (another flavivirus) has been observed in saliva, urine, and semen (with associated sexual transmission) (see  <a class="medical medical_review" href="/z/d/html/106169.html" rel="external">"Zika virus infection: An overview"</a>), and there are reports of persistent infections of related flaviviruses in animal models. Thus, further investigations on transmission should be carried out in persons infected with SLE virus.</p><p class="headingAnchor" id="H8"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Human infection with SLE virus rarely results in clinical illness. The average ratio of asymptomatic infection to symptomatic illness is 300:1 [<a href="#rid38">38</a>]. The most important risk factor for developing symptomatic encephalitis is age. Although cases of SLE have been reported in very young children [<a href="#rid52">52</a>], elderly persons are at highest risk. As an example, the ratio of symptomatic to asymptomatic infection in children is 1:800 compared to a high of 1:85 in adults over the age of 60 years [<a href="#rid38">38</a>]. The reason for this age-related susceptibility has not been defined.</p><p>Among symptomatic patients, the incubation period for SLE has been estimated to be 4 to 21 days. The spectrum of clinical illness includes nonspecific fever with headache, aseptic meningitis, and fatal meningoencephalitis [<a href="#rid53">53,54</a>]. </p><p>The severity of encephalitis and its lethality are greatest in the elderly [<a href="#rid38">38,53</a>]. It is less clear how the immune status impacts the clinical presentation. As an example, a fatal human case of SLE was described in an immunocompromised patient with lymphoma during the 2015 outbreak in California [<a href="#rid55">55</a>], and cases of SLE have been reported in patients infected with HIV [<a href="#rid29">29</a>]; however, in one small study, concomitant HIV infection did not affect the clinical presentation [<a href="#rid56">56</a>]. </p><p>During a dengue outbreak in Brazil in 2006, six cases of SLE were diagnosed by nucleic acid methods; three had viral encephalitis, and the other three had signs of hemorrhagic disease [<a href="#rid46">46</a>]. Hemorrhagic signs had not been previously associated with SLE infections, and it is difficult to draw definitive conclusions regarding a causal link with SLE virus.</p><p class="headingAnchor" id="H9"><span class="h2">Prodromal symptoms</span><span class="headingEndMark"> — </span>Prior to the appearance of central nervous system (CNS) signs, the patient with SLE virus infection experiences fever, generalized malaise, headache, and myalgias. Some patients have respiratory (cough, sore throat) or urinary tract (dysuria, urgency, incontinence) symptoms. Fever generally lasts for four to five days and may reach 40 to 41ºC. The headache is typically severe and may be accompanied by photophobia, nausea, and vomiting.</p><p class="headingAnchor" id="H10"><span class="h2">Neurologic signs</span><span class="headingEndMark"> — </span>The appearance of CNS signs is generally rapid. Children and young adults often experience a milder case of SLE, with signs of meningitis only. In more severe cases with global brain parenchymal involvement, patients exhibit altered sensorium and a wide array of neurologic abnormalities. Tremors of the eyelids, tongue, lips, and extremities occur in as many as two-thirds of patients with SLE and may persist for weeks after recovery from the acute illness. Cranial nerve dysfunction occurs in 25 percent of patients, most frequently as unilateral facial motor weakness. Other signs include loss of oculomotor function, dysarthria, and rarely loss of the olfactory sense. </p><p>Signs of thalamus, brainstem, or cerebellum infection include tremors, myoclonus, opsoclonus, nystagmus, and ataxia. Pathologic reflexes are common, but motor and sensory deficits are rare. Focal or generalized seizures have been noted in fewer than 10 percent of cases. Signs of severe increased intracranial pressure have not been reported.</p><p>Postinfectious autoimmune syndromes have been rarely linked to SLE infection. There are two case reports of SLE presenting with a clinical diagnosis of Guillain-Barré syndrome [<a href="#rid57">57</a>]. There is also one case report of acute disseminated encephalomyelitis (ADEM) following three weeks after mild SLE infection [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>The peripheral white blood cell (WBC) count is normal or may be mildly elevated, particularly in children. Alanine aminotransferase and creatine phosphokinase levels are modestly elevated in 50 to 75 percent of patients [<a href="#rid53">53</a>]. Proteinuria, microscopic hematuria, pyuria, and mild azotemia are also found in some patients. It is likely that these findings are related to the infection, as SLE viral antigen was found in urinary sediment in one study [<a href="#rid32">32</a>] and the kidney is a target organ of infection in an animal model [<a href="#rid31">31</a>]. Hyponatremia with fluid overload due to the inappropriate secretion of antidiuretic hormone (SIADH) has been documented in approximately 30 percent of patients; the syndrome is mild, and patients respond to water restriction.</p><p class="headingAnchor" id="H12"><span class="h2">Cerebrospinal fluid analysis</span><span class="headingEndMark"> — </span>The most consistent laboratory abnormalities are found in the cerebrospinal fluid (CSF). The lumbar puncture opening pressure is mildly elevated at 200 to 250 mmHg in approximately one-third of cases. CSF protein concentrations are mildly elevated at 45 to 100 mg/dL and rarely exceed 200 mg/dL, while the glucose concentrations are normal or mildly depressed. The WBC count in the CSF can vary from a few to several hundred cells, but counts exceeding 500 cells/mm3 are very rare. The proportion of mononuclear cells increases from 40 to 50 percent in CSF obtained during the initial illness to more than 80 percent by day seven. (See  <a class="medical medical_review" href="/z/d/html/1285.html" rel="external">"Cerebrospinal fluid: Physiology and utility of an examination in disease states"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Electroencephalography</span><span class="headingEndMark"> — </span>Electroencephalography (EEG) shows diffuse generalized slowing and delta wave activity; occasionally focal discharges and spike activity can be seen [<a href="#rid54">54</a>]. If EEG abnormalities are present, they do not appear to correlate well with the severity of clinical symptoms.</p><p class="headingAnchor" id="H14"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>In typical cases of SLE, no specific abnormalities have been identified on brain scans, computed tomographic scans, or magnetic resonance images; cortical edema, pathologic enhancement, and mass effect are not present. The case report of ADEM noted above that was due to SLE virus was notable for white matter signal abnormalities on magnetic nuclear imaging [<a href="#rid35">35</a>].</p><p>Studies of cerebral blood flow and metabolism in comatose patients with SLE showed reduced metabolic activity and oxygen uptake. However, blood flow was not affected [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H15"><span class="h1">OUTCOME OF INFECTION</span><span class="headingEndMark"> — </span>Death due to the virus generally occurs within the first two weeks of the onset of the infection, accompanied by coma and respiratory depression. The case-fatality rate is higher in persons over 60 years than in younger individuals (20 versus 3 to 6 percent). Case-fatality rates adjusted for age are also higher in the eastern than in the western United States, possibly reflecting differences in virulence of the viral strains.</p><p>Direct injury to the brain by the virus causes death during the first two weeks of infection; later deaths are due to complications of hospitalization, especially bronchopneumonia and pulmonary embolism. Clinical features suggesting a poor prognosis include sustained high fever, convulsions, advanced age, and severely depressed state of consciousness. In some outbreaks, an association was noted between SLE and a variety of underlying diseases, including hypertension, diabetes mellitus, alcoholism, and chronic obstructive lung disease [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Convalescence</span><span class="headingEndMark"> — </span>Most patients, particularly elderly patients, experience difficulty in regaining full health after an episode of SLE [<a href="#rid58">58</a>]. A period of prolonged convalescence, lasting weeks or even months, is characterized by headaches, anxiety, irritability, memory deficits, persistent tremor, and dizziness. Objective signs on physical examination include tremors and asymmetric reflexes. Classical Parkinsonism has not been a feature of the convalescent syndrome.</p><p class="headingAnchor" id="H17"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>SLE should be considered in all cases of viral encephalitis occurring in the summertime, but particularly in elderly patients or when two or more similar cases cluster in a community. (See  <a class="medical medical_review" href="/z/d/html/1284.html" rel="external">"Viral encephalitis in adults"</a>.) </p><p>The most important agent causing confusion is West Nile (WN) virus. Both SLE and WN virus produce a similar disease with a predilection for the elderly. Although flaccid paralysis and a polio-like syndrome appear to be more common in WN virus infection, in one report, no clinical features were helpful in differentiating patients with St. Louis and WN encephalitis [<a href="#rid59">59</a>]. SLE and WN infections must be distinguished by specific serologic tests. (See  <a class="medical medical_review" href="/z/d/html/1273.html" rel="external">"Clinical manifestations and diagnosis of West Nile virus infection"</a> and <a class="local">'Diagnosis'</a> below.)</p><p>SLE has, in occasional cases, been mistaken for stroke, heat stroke, or drug overdose. When the primary manifestation is aseptic meningitis, SLE may be difficult to distinguish from enteroviral infections. Other viral, mycoplasma, and bacterial infections of the central nervous system (CNS) can produce a similar clinical picture. By contrast, it is easier to differentiate typical cases of herpes simplex virus (HSV) encephalitis from SLE because the former is characterized by a focal presentation, convulsions, early behavioral disturbances, and an increased cerebrospinal fluid (CSF) pressure. (See  <a class="medical medical_review" href="/z/d/html/8278.html" rel="external">"Herpes simplex virus type 1 encephalitis"</a>.) </p><p>Autoimmune encephalitis, due to the presence of neuronal antibodies to cell surface or synaptic proteins, is a potentially treatable cause of encephalitis that should also be differentiated from SLE. Clinically, autoimmune encephalitis is more likely to be associated with psychosis and autonomic instability and to have brain imaging that localizes to the limbic system [<a href="#rid60">60</a>]. (See  <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">"Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Clinically, SLE may be difficult to differentiate from other causes of summer season encephalitis, including West Nile (WN). (See <a class="local">'Differential diagnosis'</a> above.)</p><p>The diagnosis of SLE is generally made by serology, particularly the IgM enzyme linked immunosorbent assay (ELISA). The presence of IgM antibodies in a single serum provides a presumptive diagnosis, and a significant rise or fall between appropriately timed acute-convalescent or early-late convalescent sera is diagnostic. However, antigenic cross-reactions with other flaviviruses, particularly WN virus, can be a problem, although use of a discriminatory algorithm for analysis of IgM ELISA successfully differentiated the infections in one report [<a href="#rid61">61</a>]. Monoclonal blocking ELISA techniques are useful in providing a specific diagnosis and have been applied to WN diagnosis in hosts previously infected with SLE [<a href="#rid62">62</a>] (see  <a class="medical medical_review" href="/z/d/html/1273.html" rel="external">"Clinical manifestations and diagnosis of West Nile virus infection", section on 'Diagnosis'</a>). Noninfectious recombinant virus-like particle antigens are useful as diagnostic reagents.</p><p>A rapid microsphere-based IgM immunoassay has been developed [<a href="#rid63">63</a>]. The ratio of IgM ELISA antibody to WN and SLE is useful in differentiating these infections [<a href="#rid64">64</a>]. Recombinant virus-like particle antigens have also been engineered to have reduced cross reactivity and may be used as antigens in serological diagnosis [<a href="#rid65">65</a>]. Use of recombinant NS5 antigen in ELISA is reported to provide a virus species specific serodiagnosis. A specific neutralization test may be necessary for definitive serologic diagnosis [<a href="#rid66">66</a>]. Chimeric viruses have also been developed for use in type-specific neutralization tests having SLE envelope proteins in a yellow fever 17D vector and can be used at the BL2 containment level [<a href="#rid67">67</a>].</p><p>It is also valuable to submit cerebrospinal fluid (CSF) for antibody testing since the finding of IgM antibody in CSF indicates brain infection and local antibody production. Polymerase chain reaction (PCR) analysis of CSF to exclude herpes simplex virus (HSV) or enteroviral infection may also be useful. In one case, metagenomic next-generation sequencing from a sample of CSF was used to diagnose SLE [<a href="#rid55">55</a>].</p><p>Virus isolation from the blood or CSF has generally been unsuccessful. However, the virus may be recovered from brain tissue, including the basal ganglia, cervical cord, and cerebellum, following inoculation of mammalian or mosquito cell culture or baby mice. Viral antigen can also be detected by immunofluorescence in brain tissue sections. There are few data on the use of PCR for detection of SLE in clinical samples.</p><p class="headingAnchor" id="H19"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H206149240"><span class="h2">Supportive care</span><span class="headingEndMark"> — </span>The optimal supportive management of patients requires attention to electrolyte and fluid balance, with water restriction, if necessary, to correct hyponatremia due to the syndrome of inappropriate antidiuretic hormone secretion and to prevent brain edema. (See  <a class="medical medical_review" href="/z/d/html/2384.html" rel="external">"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)"</a>.)</p><p>Other measures may help to prevent nosocomial complications, such as nasogastric suction to reduce the risk of aspiration, skin care, prevention of deep vein thrombosis, <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">cimetidine</a> or <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">omeprazole</a> to prevent gastric ulcer, and steps to reduce the risk of bacterial superinfections of the respiratory and urinary tracts. Mechanical ventilation may be required in patients with respiratory failure.</p><p class="headingAnchor" id="H895010838"><span class="h2">Other therapies</span><span class="headingEndMark"> — </span>No specific antiviral therapy is of proven efficacy and corticosteroids are not indicated, except in the rare case of acute demyelinating encephalomyelitis (ADEM). (See <a class="local">'Neurologic signs'</a> above.)</p><p>Some antiviral drugs have been evaluated for activity against related flaviviruses, as well as SLE virus in vitro. There is renewed interest in the use of antivirals against Zika and dengue. In addition, <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a>, an agent used to treat hepatitis C virus (a different genus in the family <em>Flaviviridae</em>), targets the NS5 polymerase, inhibits multiple flaviviruses, and has been tested in patients with yellow fever. Other drugs showing inhibitory activity include thiosemicarbazones and phthalyl-thiazoles. </p><p>Interferon alfa reduced mortality in mice when given either subcutaneously or by aerosol at the time of exposure to the virus [<a href="#rid68">68</a>]. The potential efficacy of this approach in humans was evaluated in a pilot study in which 15 patients with SLE received <a class="drug drug_general" data-topicid="8563" href="/z/d/drug information/8563.html" rel="external">interferon alfa-2b</a> were compared to 17 untreated patients with SLE admitted to the same hospital during an outbreak [<a href="#rid69">69</a>]. Interferon alfa-2b was associated with a reduced likelihood of persistence of quadriplegia, quadriparesis, or respiratory insufficiency after the first week of hospitalization (13 versus 65 percent) and after the second week (7 versus 29 percent). Transient neutropenia and/or mild hepatitis occurred in 11 treated patients. Two patients with transplant-acquired neuroinvasive SLE were treated with interferon alfa-2b and intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> and were reported to have improved within 72 hours [<a href="#rid51">51</a>]. However, production of interferon alfa-2b has been discontinued; although <a class="drug drug_general" data-topicid="10136" href="/z/d/drug information/10136.html" rel="external">pegylated interferon alfa-2a</a> is still available, this agent has not been evaluated for treatment of SLE. </p><p>Administration of high-titer antibody to animals and human patients with West Nile (WN) may be effective even after the establishment of brain infection [<a href="#rid70">70</a>]. This treatment has not been tried with SLE. There are a number of promising small molecules under investigation for treatment of dengue and WN, but the work is at an early stage and beyond the scope of this review. Antisense (RNAi) has also shown promise in animal models, although there are daunting delivery issues [<a href="#rid71">71</a>].</p><p class="headingAnchor" id="H20"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Surveillance for arbovirus infections in birds and mosquitoes has been adversely affected by funding cuts in many areas, and is currently of questionable predictive effectiveness [<a href="#rid72">72</a>]. However, mosquito control is indicated to interrupt transmission once human cases appear. Remaining indoors in properly screened areas during the late afternoon and evening may significantly reduce the risk of mosquito bites in areas where SLE cases have occurred in the past. A more detailed discussion on the prevention of insect bites is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4085.html" rel="external">"Prevention of arthropod and insect bites: Repellents and other measures"</a>.)</p><p>There is no available vaccine against SLE virus, although several experimental approaches have shown promise, including chimeric attenuated virus vectors using yellow fever 17D and dengue viruses [<a href="#rid67">67,73</a>]. There is no commercial interest in a vaccine given the low incidence of SLE. However, novel strategies for vaccination may be warranted given the unpredictable nature of SLE epidemics. One strategy is to evaluate the efficacy of a vaccine against a closely-related virus in the Japanese encephalitis (JE) serocomplex. There is experimental evidence for cross-protection from live, attenuated JE vaccines (eg, Imojev) against heterologous members of the serocomplex [<a href="#rid74">74</a>]; it is unclear whether cross-protective antibodies are elicited to SLE virus. </p><p class="headingAnchor" id="H613953007"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109959.html" rel="external">"Society guideline links: Infectious encephalitis"</a>.)</p><p class="headingAnchor" id="H4928852"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>St. Louis encephalitis (SLE) virus is a member of the family <em>Flaviviridae</em>, which includes West Nile (WN) virus, Japanese encephalitis (JE) virus, yellow fever virus, and dengue virus. (See <a class="local">'Virology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After inoculation of the virus into the human host via mosquito saliva, viral replication is initiated in local tissues and regional lymph nodes. Subsequent spread occurs initially to extraneural tissues via the lymphatics and blood. The mechanism by which SLE virus reaches the brain remains uncertain, but may include direct invasion at sites of compromised microvasculature or at the choroid plexus, where the endothelium is "fenestrated." Immune activation may play a critical role in neuroinvasion. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>SLE virus is widely distributed in the Americas. The incidence of SLE has declined in North America over the last decade due to interference in transmission cycles by WN virus. However, there are increased reports of SLE in South America, and more recently, the introduction of virulent South American strains has been associated with outbreaks in California and Arizona. SLE mainly occurs during the summer months when mosquito vectors are active. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Human infection with SLE virus only rarely results in clinical illness. The ratio asymptomatic infection to symptomatic illness is 300:1. The most important risk factor for symptomatic encephalitis is older age. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms of SLE include a prodrome of fever, malaise, headache, and myalgias, followed by changes in sensorium. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cerebrospinal fluid (CSF) protein concentrations are mildly elevated at 45 to 100 mg/dL while the glucose concentrations are normal or mildly depressed. The white blood cell (WBC) count in the CSF can vary from a few to several hundred cells, but counts exceeding 500 cells/mm3 are rare. (See <a class="local">'Cerebrospinal fluid analysis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The case-fatality rate is higher in persons over 60 years than in younger individuals. (See <a class="local">'Outcome of infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is no specific antiviral treatment or vaccine for SLE. (See <a class="local">'Treatment'</a> above and <a class="local">'Prevention'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Reisen WK. Epidemiology of St. Louis encephalitis virus. Adv Virus Res 2003; 61:139.</a></li><li><a class="nounderline abstract_t">Baillie GJ, Kolokotronis SO, Waltari E, et al. Phylogenetic and evolutionary analyses of St. Louis encephalitis virus genomes. Mol Phylogenet Evol 2008; 47:717.</a></li><li><a class="nounderline abstract_t">Reisen WK, Lothrop HD, Wheeler SS, et al. Persistent West Nile virus transmission and the apparent displacement St. Louis encephalitis virus in southeastern California, 2003-2006. J Med Entomol 2008; 45:494.</a></li><li><a class="nounderline abstract_t">Maharaj PD, Langevin SA, Bolling BG, et al. N-linked glycosylation of the West Nile virus envelope protein is not a requisite for avian virulence or vector competence. PLoS Negl Trop Dis 2019; 13:e0007473.</a></li><li><a class="nounderline abstract_t">Diaz A, Coffey LL, Burkett-Cadena N, Day JF. Reemergence of St. Louis Encephalitis Virus in the Americas. Emerg Infect Dis 2018; 24.</a></li><li><a class="nounderline abstract_t">Kramer LD, Chandler LJ. Phylogenetic analysis of the envelope gene of St. Louis encephalitis virus. Arch Virol 2001; 146:2341.</a></li><li><a class="nounderline abstract_t">Auguste AJ, Pybus OG, Carrington CV. Evolution and dispersal of St. Louis encephalitis virus in the Americas. Infect Genet Evol 2009; 9:709.</a></li><li><a class="nounderline abstract_t">Rodrigues SG, Nunes MR, Casseb SM, et al. Molecular epidemiology of Saint Louis encephalitis virus in the Brazilian Amazon: genetic divergence and dispersal. J Gen Virol 2010; 91:2420.</a></li><li><a class="nounderline abstract_t">Trent DW, Monath TP, Bowen GS, et al. Variation among strains of St. Louis encephalitis virus: basis for a genetic, pathogenetic, and epidemiologic classification. Ann N Y Acad Sci 1980; 354:219.</a></li><li><a class="nounderline abstract_t">Diaz LA, Nemeth NM, Bowen RA, et al. Comparison of argentinean saint louis encephalitis virus non-epidemic and epidemic strain infections in an avian model. PLoS Negl Trop Dis 2011; 5:e1177.</a></li><li><a class="nounderline abstract_t">Kopp A, Gillespie TR, Hobelsberger D, et al. Provenance and geographic spread of St. Louis encephalitis virus. MBio 2013; 4:e00322.</a></li><li><a class="nounderline abstract_t">Venkat H, Krow-Lucal E, Hennessey M, et al. Concurrent Outbreaks of St. Louis Encephalitis Virus and West Nile Virus Disease - Arizona, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:1349.</a></li><li><a class="nounderline abstract_t">White GS, Symmes K, Sun P, et al. Reemergence of St. Louis Encephalitis Virus, California, 2015. Emerg Infect Dis 2016; 22:2185.</a></li><li><a class="nounderline abstract_t">Ridenour CL, Cocking J, Poidmore S, et al. St. Louis Encephalitis Virus in the Southwestern United States: A Phylogeographic Case for a Multi-Variant Introduction Event. Front Genet 2021; 12:667895.</a></li><li><a class="nounderline abstract_t">Swetnam DM, Stuart JB, Young K, et al. Movement of St. Louis encephalitis virus in the Western United States, 2014- 2018. PLoS Negl Trop Dis 2020; 14:e0008343.</a></li><li><a class="nounderline abstract_t">Saiz JC, Martín-Acebes MA, Blázquez AB, et al. Pathogenicity and virulence of West Nile virus revisited eight decades after its first isolation. Virulence 2021; 12:1145.</a></li><li><a class="nounderline abstract_t">Monath TP, Cropp CB, Harrison AK. Mode of entry of a neurotropic arbovirus into the central nervous system. Reinvestigation of an old controversy. Lab Invest 1983; 48:399.</a></li><li><a class="nounderline abstract_t">Samuel MA, Wang H, Siddharthan V, et al. Axonal transport mediates West Nile virus entry into the central nervous system and induces acute flaccid paralysis. Proc Natl Acad Sci U S A 2007; 104:17140.</a></li><li class="breakAll">Gardner JJ, Reyes MG. Pathology. In: St. Louis Encephalitis, Monath TP (Ed), American Public Health Association, Washington, DC 1980. p.551.</li><li><a class="nounderline abstract_t">Wang T, Town T, Alexopoulou L, et al. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 2004; 10:1366.</a></li><li><a class="nounderline abstract_t">Samuel MA, Morrey JD, Diamond MS. Caspase 3-dependent cell death of neurons contributes to the pathogenesis of West Nile virus encephalitis. J Virol 2007; 81:2614.</a></li><li><a class="nounderline abstract_t">Moskowitz DW, Johnson FE. The central role of angiotensin I-converting enzyme in vertebrate pathophysiology. Curr Top Med Chem 2004; 4:1433.</a></li><li><a class="nounderline abstract_t">Suthar MS, Ma DY, Thomas S, et al. IPS-1 is essential for the control of West Nile virus infection and immunity. PLoS Pathog 2010; 6:e1000757.</a></li><li><a class="nounderline abstract_t">Errett JS, Suthar MS, McMillan A, et al. The essential, nonredundant roles of RIG-I and MDA5 in detecting and controlling West Nile virus infection. J Virol 2013; 87:11416.</a></li><li><a class="nounderline abstract_t">Lim JK, Louie CY, Glaser C, et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis 2008; 197:262.</a></li><li><a class="nounderline abstract_t">Pulendran B, Miller J, Querec TD, et al. Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis 2008; 198:500.</a></li><li><a class="nounderline abstract_t">McCandless EE, Zhang B, Diamond MS, Klein RS. CXCR4 antagonism increases T cell trafficking in the central nervous system and improves survival from West Nile virus encephalitis. Proc Natl Acad Sci U S A 2008; 105:11270.</a></li><li><a class="nounderline abstract_t">Diamond MS, Gale M Jr. Cell-intrinsic innate immune control of West Nile virus infection. Trends Immunol 2012; 33:522.</a></li><li><a class="nounderline abstract_t">Viloria GA, Kundro MA, Toibaro JJ, et al. Two cases of Saint Louis encephalitis in HIV-1 infected patients in Buenos Aires. Braz J Infect Dis 2011; 15:607.</a></li><li><a class="nounderline abstract_t">Shrestha B, Ng T, Chu HJ, et al. The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus. Vaccine 2008; 26:2020.</a></li><li><a class="nounderline abstract_t">Siirin MT, Duan T, Lei H, et al. Chronic St. Louis encephalitis virus infection in the golden hamster (Mesocricetus auratus). Am J Trop Med Hyg 2007; 76:299.</a></li><li><a class="nounderline abstract_t">Luby JP, Murphy FK, Gilliam JN, et al. Antigenuria in St. Louis encephalitis. Am J Trop Med Hyg 1980; 29:265.</a></li><li><a class="nounderline abstract_t">Hansen M, Nolan MS, Gorchakov R, et al. Unique Cytokine Response in West Nile Virus Patients Who Developed Chronic Kidney Disease: A Prospective Cohort Study. Viruses 2021; 13.</a></li><li><a class="nounderline abstract_t">Suzuki M, Phillips CA. St. Louis encephalitis. A histopathologic study of the fatal cases from the Houston epidemic in 1964. Arch Pathol 1966; 81:47.</a></li><li><a class="nounderline abstract_t">Sejvar JJ, Bode AV, Curiel M, Marfin AA. Post-infectious encephalomyelitis associated with St. Louis encephalitis virus infection. Neurology 2004; 63:1719.</a></li><li><a class="nounderline abstract_t">Curren EJ, Lindsey NP, Fischer M, Hills SL. St. Louis Encephalitis Virus Disease in the United States, 2003-2017. Am J Trop Med Hyg 2018; 99:1074.</a></li><li><a class="nounderline abstract_t">Reisen WK, Fang Y, Martinez VM. Avian host and mosquito (Diptera: Culicidae) vector competence determine the efficiency of West Nile and St. Louis encephalitis virus transmission. J Med Entomol 2005; 42:367.</a></li><li class="breakAll">Monath TP. Epidemiology. In: St. Louis Encephalitis, Monath TP (Ed), American Public Health Association, Washington, DC 1980. p.239.</li><li><a class="nounderline abstract_t">Monath TP, Tsai TF. St. Louis encephalitis: lessons from the last decade. Am J Trop Med Hyg 1987; 37:40S.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). West Nile virus disease and other arboviral diseases--United States, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:1009.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). West nile virus disease and other arboviral diseases - United States, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:510.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). West Nile virus and other arboviral diseases--United States, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:513.</a></li><li><a class="nounderline abstract_t">Lindsey NP, Lehman JA, Staples JE, Fischer M. West Nile Virus and Other Nationally Notifiable Arboviral Diseases - United States, 2014. MMWR Morb Mortal Wkly Rep 2015; 64:929.</a></li><li><a class="nounderline abstract_t">Spinsanti LI, Díaz LA, Glatstein N, et al. Human outbreak of St. Louis encephalitis detected in Argentina, 2005. J Clin Virol 2008; 42:27.</a></li><li><a class="nounderline abstract_t">Seijo A, Morales A, Poustis G, et al. [Outbreak of St. Louis encephalitis in the Metropolitan Buenos Aires Area]. Medicina (B Aires) 2011; 71:211.</a></li><li><a class="nounderline abstract_t">Mondini A, Cardeal IL, Lázaro E, et al. Saint Louis encephalitis virus, Brazil. Emerg Infect Dis 2007; 13:176.</a></li><li><a class="nounderline abstract_t">Pedersen K, Marks DR, Wang E, et al. Widespread Detection of Antibodies to Eastern Equine Encephalitis, West Nile, St. Louis Encephalitis, and Turlock Viruses in Various Species of Wild Birds from Across the United States. Am J Trop Med Hyg 2016; 95:206.</a></li><li><a class="nounderline abstract_t">Rosa R, Costa EA, Marques RE, et al. Isolation of saint louis encephalitis virus from a horse with neurological disease in Brazil. PLoS Negl Trop Dis 2013; 7:e2537.</a></li><li><a class="nounderline abstract_t">Shaman J, Day JF, Stieglitz M. The spatial-temporal distribution of drought, wetting, and human cases of St. Louis encephalitis in southcentral Florida. Am J Trop Med Hyg 2004; 71:251.</a></li><li><a class="nounderline abstract_t">Díaz A, Flores FS, Quaglia AI, Contigiani MS. Evaluation of Argentinean Bird Species as Amplifying Hosts for St. Louis Encephalitis Virus (Flavivirus, Flaviviridae). Am J Trop Med Hyg 2018; 99:216.</a></li><li><a class="nounderline abstract_t">Hartmann CA, Vikram HR, Seville MT, et al. Neuroinvasive St. Louis Encephalitis Virus Infection in Solid Organ Transplant Recipients. Am J Transplant 2017; 17:2200.</a></li><li><a class="nounderline abstract_t">Wootton SH, Kaplan SL, Perrotta DM, et al. St. Louis encephalitis in early infancy. Pediatr Infect Dis J 2004; 23:951.</a></li><li class="breakAll">Brinker KR, Monath TP. The acute disease. In: St. Louis Encephalitis, Monath TP (Ed), American Public Health Association, Washington, DC 1980. p.503.</li><li><a class="nounderline abstract_t">Brinker KR, Paulson G, Monath TP, et al. St Louis encephalitis in Ohio, September 1975: clinical and EEG studies in 16 cases. Arch Intern Med 1979; 139:561.</a></li><li><a class="nounderline abstract_t">Chiu CY, Coffey LL, Murkey J, et al. Diagnosis of Fatal Human Case of St. Louis Encephalitis Virus Infection by Metagenomic Sequencing, California, 2016. Emerg Infect Dis 2017; 23:1964.</a></li><li><a class="nounderline abstract_t">Okhuysen PC, Crane JK, Pappas J. St. Louis encephalitis in patients with human immunodeficiency virus infection. Clin Infect Dis 1993; 17:140.</a></li><li><a class="nounderline abstract_t">Powell KE, Blakey DL. St. Louis encephalitis: clinical and epidemiologic aspects, Mississippi, 1974. South Med J 1976; 69:1121.</a></li><li class="breakAll">Finley KH, Riggs N. Convalescence and sequelae. In: St. Louis Encephalitis, Monath TP (Ed), American Public Health Association, Washington, DC 1980. p.535.</li><li><a class="nounderline abstract_t">Venkat H, Krow-Lucal E, Kretschmer M, et al. Comparison of Characteristics of Patients with West Nile Virus or St. Louis Encephalitis Virus Neuroinvasive Disease During Concurrent Outbreaks, Maricopa County, Arizona, 2015. Vector Borne Zoonotic Dis 2020; 20:624.</a></li><li><a class="nounderline abstract_t">Armangue T, Leypoldt F, Dalmau J. Autoimmune encephalitis as differential diagnosis of infectious encephalitis. Curr Opin Neurol 2014; 27:361.</a></li><li><a class="nounderline abstract_t">Martin DA, Noga A, Kosoy O, et al. Evaluation of a diagnostic algorithm using immunoglobulin M enzyme-linked immunosorbent assay to differentiate human West Nile Virus and St. Louis Encephalitis virus infections during the 2002 West Nile Virus epidemic in the United States. Clin Diagn Lab Immunol 2004; 11:1130.</a></li><li><a class="nounderline abstract_t">Ledermann JP, Lorono-Pino MA, Ellis C, et al. Evaluation of widely used diagnostic tests to detect West Nile virus infections in horses previously infected with St. Louis encephalitis virus or dengue virus type 2. Clin Vaccine Immunol 2011; 18:580.</a></li><li><a class="nounderline abstract_t">Johnson AJ, Noga AJ, Kosoy O, et al. Duplex microsphere-based immunoassay for detection of anti-West Nile virus and anti-St. Louis encephalitis virus immunoglobulin m antibodies. Clin Diagn Lab Immunol 2005; 12:566.</a></li><li><a class="nounderline abstract_t">Curren EJ, Venkat H, Sunenshine R, et al. Assessment of Immunoglobulin M Enzyme-Linked Immunosorbent Assay Ratios to Identify West Nile Virus and St. Louis Encephalitis Virus Infections During Concurrent Outbreaks of West Nile Virus and St. Louis Encephalitis Virus Diseases, Arizona 2015. Vector Borne Zoonotic Dis 2020; 20:619.</a></li><li><a class="nounderline abstract_t">Roberson JA, Crill WD, Chang GJ. Differentiation of West Nile and St. Louis encephalitis virus infections by use of noninfectious virus-like particles with reduced cross-reactivity. J Clin Microbiol 2007; 45:3167.</a></li><li><a class="nounderline abstract_t">Simari MB, Goñi SE, Luppo VC, et al. Specific diagnostic method for St. Louis encephalitis virus using a non-structural protein as the antigen. J Gen Virol 2020; 101:168.</a></li><li><a class="nounderline abstract_t">Pugachev KV, Guirakhoo F, Mitchell F, et al. Construction of yellow fever/St. Louis encephalitis chimeric virus and the use of chimeras as a diagnostic tool. Am J Trop Med Hyg 2004; 71:639.</a></li><li><a class="nounderline abstract_t">Brooks TJ, Phillpotts RJ. Interferon-alpha protects mice against lethal infection with St Louis encephalitis virus delivered by the aerosol and subcutaneous routes. Antiviral Res 1999; 41:57.</a></li><li><a class="nounderline abstract_t">Rahal JJ, Anderson J, Rosenberg C, et al. Effect of interferon-alpha2b therapy on St. Louis viral meningoencephalitis: clinical and laboratory results of a pilot study. J Infect Dis 2004; 190:1084.</a></li><li><a class="nounderline abstract_t">Makhoul B, Braun E, Herskovitz M, et al. Hyperimmune gammaglobulin for the treatment of West Nile virus encephalitis. Isr Med Assoc J 2009; 11:151.</a></li><li><a class="nounderline abstract_t">Stein DA, Shi PY. Nucleic acid-based inhibition of flavivirus infections. Front Biosci 2008; 13:1385.</a></li><li><a class="nounderline abstract_t">Hadler JL, Patel D, Nasci RS, et al. Assessment of Arbovirus Surveillance 13 Years after Introduction of West Nile Virus, United States. Emerg Infect Dis 2015; 21:1159.</a></li><li><a class="nounderline abstract_t">Blaney JE Jr, Speicher J, Hanson CT, et al. Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys. Vaccine 2008; 26:4150.</a></li><li><a class="nounderline abstract_t">Lobigs M, Diamond MS. Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex. Expert Rev Vaccines 2012; 11:177.</a></li></ol></div><div id="topicVersionRevision">Topic 1288 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14714432" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Epidemiology of St. Louis encephalitis virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18374605" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Phylogenetic and evolutionary analyses of St. Louis encephalitis virus genomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18533445" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Persistent West Nile virus transmission and the apparent displacement St. Louis encephalitis virus in southeastern California, 2003-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31306420" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : N-linked glycosylation of the West Nile virus envelope protein is not a requisite for avian virulence or vector competence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30457961" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Reemergence of St. Louis Encephalitis Virus in the Americas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11811684" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Phylogenetic analysis of the envelope gene of St. Louis encephalitis virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18708161" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Evolution and dispersal of St. Louis encephalitis virus in the Americas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20592112" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Molecular epidemiology of Saint Louis encephalitis virus in the Brazilian Amazon: genetic divergence and dispersal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6261645" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Variation among strains of St. Louis encephalitis virus: basis for a genetic, pathogenetic, and epidemiologic classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21629729" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Comparison of argentinean saint louis encephalitis virus non-epidemic and epidemic strain infections in an avian model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23760463" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Provenance and geographic spread of St. Louis encephalitis virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26656306" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Concurrent Outbreaks of St. Louis Encephalitis Virus and West Nile Virus Disease - Arizona, 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27869600" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Reemergence of St. Louis Encephalitis Virus, California, 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34168675" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : St. Louis Encephalitis Virus in the Southwestern United States: A Phylogeographic Case for a Multi-Variant Introduction Event.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32520944" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Movement of St. Louis encephalitis virus in the Western United States, 2014- 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33843445" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pathogenicity and virulence of West Nile virus revisited eight decades after its first isolation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6300550" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Mode of entry of a neurotropic arbovirus into the central nervous system. Reinvestigation of an old controversy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17939996" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Axonal transport mediates West Nile virus entry into the central nervous system and induces acute flaccid paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17939996" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Axonal transport mediates West Nile virus entry into the central nervous system and induces acute flaccid paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15558055" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17192305" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Caspase 3-dependent cell death of neurons contributes to the pathogenesis of West Nile virus encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15379656" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The central role of angiotensin I-converting enzyme in vertebrate pathophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20140199" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : IPS-1 is essential for the control of West Nile virus infection and immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23966395" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The essential, nonredundant roles of RIG-I and MDA5 in detecting and controlling West Nile virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18179388" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18598196" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18678898" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : CXCR4 antagonism increases T cell trafficking in the central nervous system and improves survival from West Nile virus encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22726607" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cell-intrinsic innate immune control of West Nile virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22218524" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Two cases of Saint Louis encephalitis in HIV-1 infected patients in Buenos Aires.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18339459" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17297039" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Chronic St. Louis encephalitis virus infection in the golden hamster (Mesocricetus auratus).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6989277" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Antigenuria in St. Louis encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33671257" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Unique Cytokine Response in West Nile Virus Patients Who Developed Chronic Kidney Disease: A Prospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5900447" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : St. Louis encephalitis. A histopathologic study of the fatal cases from the Houston epidemic in 1964.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15534266" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Post-infectious encephalomyelitis associated with St. Louis encephalitis virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30182919" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : St. Louis Encephalitis Virus Disease in the United States, 2003-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15962789" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Avian host and mosquito (Diptera: Culicidae) vector competence determine the efficiency of West Nile and St. Louis encephalitis virus transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15962789" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Avian host and mosquito (Diptera: Culicidae) vector competence determine the efficiency of West Nile and St. Louis encephalitis virus transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3318523" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : St. Louis encephalitis: lessons from the last decade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21814163" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : West Nile virus disease and other arboviral diseases--United States, 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22785342" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : West nile virus disease and other arboviral diseases - United States, 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23803959" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : West Nile virus and other arboviral diseases--United States, 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26334477" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : West Nile Virus and Other Nationally Notifiable Arboviral Diseases - United States, 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18249032" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Human outbreak of St. Louis encephalitis detected in Argentina, 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21745768" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : [Outbreak of St. Louis encephalitis in the Metropolitan Buenos Aires Area].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17370543" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Saint Louis encephalitis virus, Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27162269" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Widespread Detection of Antibodies to Eastern Equine Encephalitis, West Nile, St. Louis Encephalitis, and Turlock Viruses in Various Species of Wild Birds from Across the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24278489" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Isolation of saint louis encephalitis virus from a horse with neurological disease in Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15381802" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The spatial-temporal distribution of drought, wetting, and human cases of St. Louis encephalitis in southcentral Florida.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29761767" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Evaluation of Argentinean Bird Species as Amplifying Hosts for St. Louis Encephalitis Virus (Flavivirus, Flaviviridae).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28452107" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Neuroinvasive St. Louis Encephalitis Virus Infection in Solid Organ Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15602196" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : St. Louis encephalitis in early infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15602196" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : St. Louis encephalitis in early infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/443951" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : St Louis encephalitis in Ohio, September 1975: clinical and EEG studies in 16 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28930022" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Diagnosis of Fatal Human Case of St. Louis Encephalitis Virus Infection by Metagenomic Sequencing, California, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8353238" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : St. Louis encephalitis in patients with human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/968523" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : St. Louis encephalitis: clinical and epidemiologic aspects, Mississippi, 1974.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/968523" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : St. Louis encephalitis: clinical and epidemiologic aspects, Mississippi, 1974.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32251616" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Comparison of Characteristics of Patients with West Nile Virus or St. Louis Encephalitis Virus Neuroinvasive Disease During Concurrent Outbreaks, Maricopa County, Arizona, 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24792345" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Autoimmune encephalitis as differential diagnosis of infectious encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15539517" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Evaluation of a diagnostic algorithm using immunoglobulin M enzyme-linked immunosorbent assay to differentiate human West Nile Virus and St. Louis Encephalitis virus infections during the 2002 West Nile Virus epidemic in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21346058" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Evaluation of widely used diagnostic tests to detect West Nile virus infections in horses previously infected with St. Louis encephalitis virus or dengue virus type 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15879016" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Duplex microsphere-based immunoassay for detection of anti-West Nile virus and anti-St. Louis encephalitis virus immunoglobulin m antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32315576" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Assessment of Immunoglobulin M Enzyme-Linked Immunosorbent Assay Ratios to Identify West Nile Virus and St. Louis Encephalitis Virus Infections During Concurrent Outbreaks of West Nile Virus and St. Louis Encephalitis Virus Diseases, Arizona 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17715375" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Differentiation of West Nile and St. Louis encephalitis virus infections by use of noninfectious virus-like particles with reduced cross-reactivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31846411" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Specific diagnostic method for St. Louis encephalitis virus using a non-structural protein as the antigen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15569798" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Construction of yellow fever/St. Louis encephalitis chimeric virus and the use of chimeras as a diagnostic tool.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10321579" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Interferon-alpha protects mice against lethal infection with St Louis encephalitis virus delivered by the aerosol and subcutaneous routes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15319857" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effect of interferon-alpha2b therapy on St. Louis viral meningoencephalitis: clinical and laboratory results of a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19544704" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Hyperimmune gammaglobulin for the treatment of West Nile virus encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17981637" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Nucleic acid-based inhibition of flavivirus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26079471" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Assessment of Arbovirus Surveillance 13 Years after Introduction of West Nile Virus, United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18586359" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22309667" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
